Ulrich BrinkmannExpert Scientist and Scientific Director at Roche Innovation Center MunichSpeaker
Profile
Dr. Ulrich Brinkmann is a member of Roche’s Large Molecule Research organization within Pharma Research & Early Development at the Roche Innovation Center Munich (Penzberg, Germany). His work focuses on protein & antibody engineering, bispecifics, and on delivery platforms for targeted payload delivery. Prior to joining Roche, he served as CSO in functional genomics and pharmacogenetics companies Xantos and Epidauros. His early work in the Molecular Biology Lab of Ira Pastan at the NIH/NCI focused on antibody stabilization and engineering technologies, and on generating recombinant immunotoxins for cancer therapy. Dr. Brinkmann is author of numerous publications and inventor of many patents covering recombinant antibodies, pharmaco- & functional genomics, immunotoxins and protein engineering technologies and applications.
Agenda Sessions
Applications of Prodrug-Activating Chain Exchange (PACE) to Enable Conditional Activation of Therapeutic Antibodies
, 13:45View Session
